

Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 3 of a 3-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Data from the Phase III AMPLIFY trial reported a statistically significant improvement in progression-free survival (PFS) with which Bruton tyrosine kinase inhibitor combined with venetoclax, with or without obinutuzumab, in comparison to chemoimmunotherapy for patients with untreated chronic lymphocytic leukemia (CLL)?**
 - a. Fixed-duration ibrutinib
 - b. Fixed-duration pirtobrutinib
 - c. Fixed-duration acalabrutinib**
 - d. Fixed-duration zanubrutinib
- 2. The ongoing Phase III CELESTIAL-TNCLL trial for patients with treatment-naïve CLL is evaluating the novel Bcl-2 inhibitor sonrotoclax in combination with which of the following agents?**
 - a. Acalabrutinib
 - b. Ibrutinib
 - c. Pirtobrutinib
 - d. Zanubrutinib**
- 3. The Phase III BRUIN CLL-321 trial of pirtobrutinib versus idelalisib with bendamustine/rituximab (BR) for patients with previously treated CLL/small lymphocytic lymphoma demonstrated which of the following outcomes?**
 - a. No statistically significant improvements in PFS and time to next treatment were observed with pirtobrutinib compared to idelalisib/BR
 - b. A statistically significant improvement in PFS, but not in time to next treatment, was observed with pirtobrutinib compared to idelalisib/BR
 - c. Statistically significant improvements in PFS and time to next treatment were observed with pirtobrutinib compared to idelalisib/BR**
- 4. An analysis of the activity of pirtobrutinib in the subgroup of patients with Richter's transformation enrolled in the BRUIN trial demonstrated which of the following outcomes?**
 - a. Half of the patients achieved a clinical response, but no complete responses were observed
 - b. Half of the patients achieved a clinical response, and several complete responses were observed**
 - c. A small minority of patients achieved a clinical response
- 5. A Phase II trial evaluating a time-limited regimen combining pirtobrutinib, venetoclax and obinutuzumab as first-line therapy for patients with CLL reported which observation in terms of rates of undetectable minimal residual disease (uMRD)?**
 - a. Rates of uMRD were low at all tested time points
 - b. Rates of uMRD were low initially and increased over time
 - c. Rates of uMRD were high at all tested time points**